To evaluate the influence of defective FA pathway in regards to cell viability following exposure to the PARP inhibitors veliparib (ABT-888) and BMN673, we treated the FA defective NSCLC cell lines H1299D2-down and A549D2-down, as well as their FA competent counterparts (H1299E and A549E) (empty vectors) with veliparib at a dose of 5 μM or BMN673 at dose of 0.5 μM. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.